Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Amit Sanyal, MD: A Clinician’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Nov
25
Today In Oncology
FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma
AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo